Fig. 2From: Optimization of combined temozolomide and peptide receptor radionuclide therapy (PRRT) in mice after multimodality molecular imaging studiesDose-finding study: H69 tumour volume as a percentage compared with day 0 (±SD) after treatment with different amounts of 177Lu-TATE, seven mice/groupBack to article page